New drug doubles 1-year survival in pancreatic cancer trial

medicalxpress - Pancreatic cancer is one of the deadliest cancers and among the hardest to treat, with most patients surviving less than a year after diagnosis. But a new drug developed at Northwestern University may soon help patients live longer.

AI Summary: A Phase 3 study showed a novel agent markedly lengthened survival for people with metastatic pancreatic cancer, roughly doubling one-year survival versus standard care. The results, from the RASolute 302 program evaluating daraxonrasib/Revolution Medicines’ approach, represent an uncommon advance in a stubbornly lethal disease and could change treatment standards pending regulatory review.

• Clinicians celebrate landmark KRAS win; cautious optimism prevails (7)
• Daraxonrasib Phase 3: drug doubles one-year survival (5)
• Market scramble: Revolution Medicines' fundraising and buyout buzz (3)
• Other pancreatic research, methods and early-stage KRAS studies (5)
• All Other Stories

Clinicians celebrate landmark KRAS win; cautious optimism prevails

Daraxonrasib Phase 3: drug doubles one-year survival

Market scramble: Revolution Medicines' fundraising and buyout buzz

Other pancreatic research, methods and early-stage KRAS studies

All Other Stories